Cecilia Renzulli
Bologna, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis.
Journal: Neurogastroenterology and motility
Published: September 29, 2021
The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis.
Journal: Journal of Crohn's & colitis
Published: September 11, 2021
Editorial: on the road towards treatment of gastroparesis-accelerating, but do we get closer? Authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: June 25, 2021
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study.
Journal: Alimentary pharmacology & therapeutics
Published: September 15, 2020
Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention.
Journal: Frontiers in pharmacology
Published: May 27, 2018
Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans.
Journal: Gastroenterology
Published: October 20, 2016
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic.
Journal: Pharmacological research
Published: August 08, 2015
Rifaximin: beyond the traditional antibiotic activity.
Journal: The Journal of antibiotics
Published: May 14, 2014
Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?
Journal: Journal of clinical gastroenterology
Published: June 12, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026